Show simple item record

Editorial: tofacitinib and biologics for moderate-to-severe ulcerative colitis—what is best in class? Authors’ reply

dc.contributor.authorBonovas, S.en
dc.contributor.authorLytras, T.en
dc.contributor.authorNikolopoulos, G.en
dc.contributor.authorPeyrin‐Biroulet, L.en
dc.contributor.authorDanese, S.en
dc.creatorBonovas, S.en
dc.creatorLytras, T.en
dc.creatorNikolopoulos, G.en
dc.creatorPeyrin‐Biroulet, L.en
dc.creatorDanese, S.en
dc.date.accessioned2021-02-23T14:38:23Z
dc.date.available2021-02-23T14:38:23Z
dc.date.issued2018
dc.identifier.issn1365-2036
dc.identifier.urihttp://gnosis.library.ucy.ac.cy/handle/7/64078
dc.description.abstractLinked Content This article is linked to Bonovas et al and Tsai papers. To view these articles visit https://doi.org/10.1111/apt.14449 and https://doi.org/10.1111/apt.14480.en
dc.language.isoenen
dc.sourceAlimentary Pharmacology & Therapeuticsen
dc.source.urihttps://onlinelibrary.wiley.com/doi/abs/10.1111/apt.14486
dc.titleEditorial: tofacitinib and biologics for moderate-to-severe ulcerative colitis—what is best in class? Authors’ replyen
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1111/apt.14486
dc.description.volume47
dc.description.issue4
dc.description.startingpage540
dc.description.endingpage541
dc.author.facultyΙατρική Σχολή / Medical School
dc.author.departmentΙατρική Σχολή / Medical School
dc.type.uhtypeArticleen
dc.contributor.orcidBonovas, S. [0000-0001-6102-6579]
dc.contributor.orcidDanese, S. [0000-0001-7341-1351]
dc.contributor.orcidNikolopoulos, G. [0000-0002-3307-0246]
dc.gnosis.orcid0000-0001-6102-6579
dc.gnosis.orcid0000-0001-7341-1351
dc.gnosis.orcid0000-0002-3307-0246


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record